{
    "clinical_study": {
        "@rank": "158063", 
        "arm_group": [
            {
                "arm_group_label": "Digoxin", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1"
            }, 
            {
                "arm_group_label": "Evacetrapib + Digoxin", 
                "arm_group_type": "Experimental", 
                "description": "130 mg evacetrapib administered orally, QD for 14 days (Days 6 to 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to determine how much digoxin gets into the blood stream\n      and how long it takes the body to get rid of it when given with the study drug evacetrapib.\n      This study will also look at the effect of evacetrapib on the removal of digoxin from the\n      body by the kidneys.  Information about any side effects that may occur will be collected.\n      This study will last approximately 33 days for each participant, not including screening."
        }, 
        "brief_title": "A Study of Evacetrapib and Digoxin in Healthy Participants", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy males and females (of non child-bearing potential)\n\n          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)\n\n          -  Normal renal function\n\n        Exclusion Criteria:\n\n          -  Participants who currently smoke or use tobacco or nicotine products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897493", 
            "org_study_id": "14619", 
            "secondary_id": "I1V-MC-EIAQ"
        }, 
        "intervention": [
            {
                "arm_group_label": "Evacetrapib + Digoxin", 
                "description": "Administered orally", 
                "intervention_name": "Evacetrapib", 
                "intervention_type": "Drug", 
                "other_name": "LY2484595"
            }, 
            {
                "arm_group_label": "Digoxin", 
                "description": "Administered orally", 
                "intervention_name": "Digoxin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Digoxin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK):  Maximum Observed Drug Concentration (Cmax) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 120 hours post-dose Day 1 and 15"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0-\u221e]) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 120 hours post-dose Day 1 and 15"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (tmax) of Digoxin", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 120 hours post-dose Day 1 and 15"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897493"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Renal Clearance (CLr) of Digoxin", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to 24 hours post dose Day 1 and 15"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}